Pfizer moves to acquire majority stake in Icagen

4.6 million Icagen shares tendered

NEW YORK — Pfizer has completed its initial cash tender offer for all the shares of drug maker Icagen that it doesn't already own, Pfizer said Tuesday.

Pfizer, which already owns an 11% stake in Icagen, announced Thursday that it would acquire a majority stake in the company. As of Friday, when the initial tender offer period expired, about 4.6 million shares of Icagen had been put up for sale; combined with Pfizer's existing stake, this represents about 64% of the North Carolina-based maker of drugs for pain, epilepsy and inflammation.

Pfizer is offering Icagen shareholders $6 per share and said the new offering period would expire next Monday, at which point any shares put up for sale will be accepted for payment immediately.

Login or Register to post a comment.